Skip to main content
Premium Trial:

Request an Annual Quote

Steve Lombardi Joins IntegraGen; David King Goes to Guava; Pharmacopeia Drug Discovery Nabs Leslie Brown; Congressman James Greenwood to Head BIO

NEW YORK, July 27 (GenomeWeb News) - CytRx said this week that it has named Benjamin Levin as the company's new general counsel, vice president of legal affairs, and corporate secretary.


According to CytRx, Levin has spent the last four years at the firm of O'Melveny & Myers as a transactional lawyer. He graduated from StanfordLawSchool, and holds a BS in economics from the Massachusetts Institute of Technology.


Proteomics company Power3 has appointed Zouhair Atassi and Thomas Watts to the company's scientific advisory board.


Atassi is currently chair of chemistry and professor of biochemistry and molecular biology at the Universityof Birmingham in the UK. He was the 2003 president of the Instituteof Immunobiology, and is the current editor-in-chief for the The Protein Journal, Protein Reviews, and Critical Reviews in Immunology.


Watts is a resident physician at the Kelsey-Seybold Clinic in The Woodlands, Tex. Watts practiced medicine at the BlueEarthMedicalCenter from 1975 to 1996, and received his MD from Baylor College of Medicine in 1972.


Steve Lombardi is the new non-executive director of IntegraGen, the company said. Lombardi is currently senior vice president of corporate development at Affymetrix. Prior to these, he spent 16 years at Applied Biosystems, finishing his career there as senior vice president of applications and products.


Guava Technologies has named David King as vice president of product development, the company said last week.


King joins Guava from Iolon, a privately-held manufacturer of tunable optical components, where he was head of new product development and product integration. Prior to this, he was principal engineer at Agilent Technologies. He has also been employed by Hewlett Packard.


King received his MS and PhD in applied physics from StanfordUniversity.


William Spencer has joined Branford, Conn.-based 454 Life Sciences as strategic marketing manager. Spencer joins 454 from OpGen, where he most recently served as director of business development.


Pharmacopeia Drug Discovery has named Leslie Brown as president and chief executive officer, the company announced last week.


Most recently, Brown served as chief operating officer at Iconix Pharmaceuticals. He has also been the chief operating officer at functional genomics company GeneTrace. From 1990 to 2000, Brown held a number of senior positions at Berlex/Schering AG including corporate vice president of Berlex Labs and president of Schering Berlin Venture.


Brown received his PhD from the Universityof Michigan, and was an NIH postdoctoral fellow at Harvard with Nobel laureate professor R.B. Woodward.


Congressman James Greenwood, who recently held hearings on Capitol Hill to see whether two proteomics researchers at the National Cancer Institute violated conflict of interest rules, will leave the US House of Representatives to become president of the Biotechnology Industry Organization. He replaces Carl Feldbaum.


Greewood, who represents Bucks County, Pa., cancelled congressional hearings on the link between antidepressants and suicide this week to avoid the appearance of a conflict of interest. As BIO president, Greenwood will be paid an annual base salary of $650,000, plus bonus incentives worth $200,000, according to news reports. He earned $158,100 as a US representative.


Greenwood, a Republican, is chairman of the US Congressional Subcommittee on Oversight and Investigations, which has been investigating consulting and awards ethics at the NIH during a series of hearings earlier this month. He has called NCI and US Food and Drug Administration approval of consulting activities by Emanuel Petricoin and Lance Liotta of the NCI-FDA Clinical Proteomics program an "outrage." For further details, read the story in the 5/21/04 issue of ProteoMonitor, GenomeWeb News' sister publication.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.